Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 4

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 1(2)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07426484Phase 4Not Yet Recruiting

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Role: collaborator

NCT04786964Phase 3Terminated

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

Role: lead

NCT03212404Phase 1Active Not Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Role: lead

NCT02926768Phase 1Completed

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Role: lead

All 4 trials loaded